Review of the safety, efficacy, costs and patient acceptability of recombinant follicle-stimulating hormone for injection in assisting ovulation induction in infertile women

Marleen Nahuis1,2,3, Fulco van der Veen1, Jur Oosterhuis2, Ben Willem Mol1, Peter Hompes3, Madelon van Wely1

1Center for Reproductive Medicine, Department of Obstetrics and Gynaecology (H4-205), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; 2Department of Obstetrics and Gynaecology, Medisch Spectrum Twente, Enschede, The Netherlands; 3Department of Obstetrics and Gynaecology, Free Medical University, Amsterdam, The Netherlands

Abstract: Anovulation is a common cause of female subfertility. Treatment of anovulation is aimed at induction of ovulation. In women with clomiphene-citrate resistant WHO group II anovulation, one of the treatment options is ovulation induction with exogenous follicle-stimulating hormone (FSH or follitropin). FSH is derived from urine or is produced as recombinant FSH. Two forms of recombinant FSH are available – follitropin alpha and follitropin beta. To evaluate the efficacy, safety, costs and acceptability of recombinant FSH, we performed a review to compare recombinant FSH with urinary-derived FSH products. Follitropin alpha, beta and urinary FSH products appeared to be equally effective in terms of pregnancy rates. Patient safety was also found to be comparable, as the incidence of side effects including multiple pregnancies was similar for all FSH products. In practice follitropin alpha and beta may be more convenient to use due to the ease of self-administration, but they are also more expensive than the urinary products.

Keywords: follitropin alpha, follitropin beta, urinary gonadotropins, polycystic ovary syndrome

Introduction

Anovulation is a common cause of infertility in women. It is classified by the World Health Organization (WHO) criteria according to endogenous concentrations of serum FSH and estradiol. About 80% of anovulatory women have WHO type II or normogonadotropic normoestrogenic anovulation. Polycystic ovary syndrome (PCOS) is the most common form of WHO II anovulatory infertility.

Gonadotropins have successfully been used for ovulation induction in anovulatory women. At present there are two classes of FSH-containing pharmaceutical preparations, those derived from the urine of postmenopausal women and those manufactured with recombinant DNA technology.

Gonadotropins are indicated for the induction of ovulation in the anovulatory infertile patient and for the development of multiple follicles in the ovulatory patient undergoing intra-uterine insemination or participating in an Assisted Reproductive Technology program.1

This review aims to evaluate the efficacy, safety and patient acceptability of recombinant gonadotropins in ovulation induction in PCOS women. A short history of the development of the various FSH products is initially described, followed by their pharmacokinetics and isoform profiles. The review then looks into the efficacy,
safety profiles and patient satisfaction of these products used for ovulation induction in comparison with urinary-derived gonadotropins.

Short history of gonadotropins development

By the late 1950s human pituitary extracts were successfully used for ovulation induction in hypogonadotropic women. Since then, human-derived gonadotropin preparations have evolved as the mainstay of ovulation induction therapy. The use of pituitary extracts was abandoned because of scarcity of available human pituitary glands and the fear of Creutzfeld-Jakob virus.

Pituitary gonadotropins were replaced by urinary derived human menopausal gonadotropins by the early 1960s, when the first report was published on its use for the treatment of ovulatory dysfunction.

Human menopausal gonadotropins consist of a purified preparation of gonadotropins extracted from the urine of postmenopausal women. The generic name is menotropins. They are inactive orally and are given by intramuscular injections. Menotropins were initially only 5% pure, contained equal amounts of luteinizing hormone (LH) and FSH and large quantities of potentially allergenic urinary proteins.

The next group of gonadotropins to emerge were purified FSH preparations or urofollitropins. Urinary FSH contained less than 1% LH but was still contaminated with 95% of nongonadotrophin-related proteins. In the mid 1990s highly purified urinary FSH became available containing less than 0.1% LH and virtually no urinary proteins, allowing subcutaneous administration.

The production of highly purified FSH was enabled by the development and application of production techniques based on immuno affinity chromatography with monoclonal antibodies.

One cycle of treatment with gonadotropins requires 20 to 30 L of urine from postmenopausal women. The increased demand for gonadotropins and the advances in molecular technology lead to the production of recombinant FSH. This was also driven by the fear of infections, for example Creutzveld-Jakob virus, although no infectivity from the Creutzveld-Jakob virus, although no infectivity from the urinary products in that they contain less acidic isoforms.

The terminal sialylation of human FSH determines the overall charge of the molecule. The iso-electric point can range from 3.5 to 7.0.

The recombinant FSH products differ from the urinary products in that they contain less acidic FSH isoforms. Slightly different purification processes affect the carbohydrate compositions. The isoform profile of both recombinant preparations are similar, although follitropin alpha is less acidic due to the larger extent of basic isoforms (isoform ranges [4–5] compared with follitropin beta [isoform ranges 3.5–5.5]).

FSH: pharmacokinetics and isoforms

FSH is a glycosylated hormone and is composed of two noncovalently linked polypeptide chains, an alpha and a beta subunit. In this heterodimeric structure the alpha and beta subunits confer its biological and immunological activity. The alpha unit is similar to other pituitary and placenta hormones (LH, thyroid-stimulating hormone [TSH] and human chorionic gonadotropin [hCG]). The oligosaccharides in the beta subunit of FSH are highly variable and the composition and complexity of the attached carbohydrate moieties may differ. Each oligosaccharide may show single branched, di- tri- and even tetrabranched structures. Each branch of the oligosaccharides determines the terminal sialylation of the negatively charged FSH molecule and so a number of isoforms exist. In humans 20 different FSH isoforms have been identified. The liver metabolism of FSH isoforms with a high number of sialic acid residues (ie, acidic isoforms) is considerably lower compared to isoforms with a low content of sialic acid residues (ie, less acidic isoforms). As a consequence, the plasma half-life of the most acidic isoforms is about 240 minutes, while the least acidic isoforms have a plasma half-life of about 180 minutes.

The terminal sialylation of human FSH determines the overall charge of the molecule. The iso-electric point can range from 3.5 to 7.0. The recombinant FSH products differ from the urinary products in that they contain less acidic FSH isoforms. Slightly different purification processes affect the carbohydrate compositions. The isoform profile of both recombinant preparations are similar, although follitropin alpha is less acidic due to the larger extent of basic isoforms (isoform ranges [4–5] compared with follitropin beta [isoform ranges 3.5–5.5]).

Ovulation induction

An indication for the use of gonadotropins is anovulation not responding to clomiphene citrate. There are three classes of anovulation, ie, WHO I, WHO II and WHO III. Women with WHO class I anovulation, which accounts for 10% of anovulatory women, have low or low–normal serum FSH concentrations and low serum estradiol concentrations due to
decreased hypothalamic secretion of gonadotropin-releasing hormone (GnRH) or pituitary unresponsiveness to GnRH. The causes of hypothalamic amenorrhea include stress- or exercise-related amenorrhea, anorexia nervosa and Kallmann syndrome.

The majority of women with WHO type I anovulation do not have the threshold levels of endogenous LH required to achieve optimal follicular development and steroidogenesis during therapy with FSH alone. Most important is that no term pregnancy occurred with this treatment. In these women an exogenous supply of LH is required to achieve an adequate follicular response. At present women with hypogonadotropic anovulation are most commonly being treated with human menopausal gonadotropin (hMG) or, mostly in a trial context, with a combination of recombinant FSH (rFSH) and LH.

About 80% of the women that suffer from infertility due to anovulation have WHO class II anovulation. The majority of these women have polycystic ovary syndrome (PCOS). The most recently developed criteria for PCOS require the presence of at least two of the following three criteria: oligo- and or anovulation, hyperandrogenism (clinical or biochemical) and ultrasonic appearance of polycystic ovaria. The conventional treatment of WHO class II anovulatory women is clomiphene citrate with or without metformin, which will restore ovulation in almost 80% of women and will result in pregnancy in 50% of all women. In women with clomiphene resistance and clomiphene failure, gonadotropins are the next line of treatment.

**Ovulation induction in women with PCOS**

Ovulation induction with gonadotropins carries a risk for multiple follicular development and multiple pregnancies. A chronic low-dose step-up regimen was introduced to reduce the incidence of these complications. Following spontaneous or progesterone induced bleeding, a course of 37.5 IU to 75 IU of daily FSH treatment is commenced on day 3 of the cycle until ovulation is induced. This starting dose is continued for 14 days. Ovarian response is monitored by transvaginal ultrasound and incremental FSH doses are given until an adequate response has been achieved. If a dominant follicle emerges, the dose of FSH is maintained until the follicle reaches a main diameter of 17 mm or above. At this point HCG is injected. With more than 3 dominant follicles the cycle is cancelled. The low-dose step-up protocol has a clinical pregnancy rate of about 20% per cycle, an incidence of ovarian hyperstimulation syndrome (OHSS) of 1% to 3% and a multiple pregnancy rate ranging from 10% to 25%.

**Efficacy, safety and cost of ovulation induction with recombinant FSH; a literature search**

In a Cochrane library meta-analysis from 2001, the efficacy of urinary FSH (uFSH) and rFSH for induction of ovulation was compared in clomiphene resistant and anovulatory women. Three randomized controlled trials were included. Two trials compared follitropin alpha with highly purified uFSH (HP uFSH) and the third trial compared follitropin beta with HP uFSH. No significant differences were found between the two treatment groups in ovulation rate, pregnancy rate, miscarriage, multiple pregnancy rate. The review concluded that there was no evidence of a difference between both rFSH and HP uFSH for ovulation induction in women with PCOS.

We searched the literature for more recent data. A trial was included if it dealt with the use of follitropin alpha versus follitropin beta or recombinant gonadotropins versus urinary gonadotropins. To identify all relevant trials we searched the Embase (1966 to November 2008) and Medline databases (1988–November 2008).

Unfortunately most studies did not differentiate between women with clomiphene resistance and clomiphene failure, which is why we included both categories in our review.

We considered the following outcome measures after the first treatment cycle:

1. Pregnancy outcomes and ovulation: live birth rate per woman, ongoing pregnancy rate per woman, clinical pregnancy rate per woman and ovulation rate per cycle.
2. Unintended effects: OHSS per cycle, multiple pregnancy rate per woman and local and systemic side effects per woman.

We identified 9 relevant randomized controlled trials that compared recombinant FSH with urinary gonadotropins. One trial was excluded as it studied differential effects on hemostasis. A further 2 trials were excluded as pregnancy results after 1 treatment cycle could not be extracted. Two trials reported the data of 3 treatment cycles, without reporting the results of the first treatment cycle.
A detailed description of the 6 trials included in this review is given in Table 1. Four trials compared follitropin alpha with HP urofollitropin.25,26,28,31 One trial compared follitropin alpha with highly purified HMG30 and 1 trial compared follitropin beta with HP urofollitropin.27 The starting dose in these trials varied between 37 and 75 IU per day.

When at least 2 trials studied a similar comparison, data were pooled and a summary statistic was calculated using a fixed-effects model. For dichotomous data a pooled (odds ratio, OR) with 95% confidence interval (CI) was calculated using the Peto method. For continuous data the mean differences were pooled and a mean weighted difference with 95% CI was calculated. Review Manager Software (RevMan 5, Cochrane Collaboration, Oxford, UK) was used for statistical analysis.

Pregnancy outcomes and ovulation
All dichotomous outcomes for the trials comparing recombinant gonadotropins and urinary gonadotropins are summarized in Figure 1. None of the included 6 trials found a significant difference for any of the reported pregnancy outcomes.

Four trials reported data on live birth rate per women after the first treatment cycle. Pooling the data resulted in an OR of 1.12 (95% CI 0.75–1.66) for recombinant gonadotropins versus urinary gonadotropins.25,28,30,31

Ongoing pregnancy rate data were reported in 3 trials.27,28,30 Pooling the ongoing pregnancy rate data of the 3 trials resulted in an OR of 1.27 (95% CI 0.78–2.07).

Clinical pregnancy rate data were reported in 3 trials.26,28,30 Pooling the clinical pregnancy rate data of these trials resulted in an OR of 1.13 (95% CI 0.67–1.89).

All 6 trials reported data on ovulation rate. Pooling these data resulted in a significantly higher ovulation rate after rFSH in comparison to urinary gonadotrophins (OR 1.40; 95% CI 1.03–1.92).25–28,30,31 Hence, significantly more women were ovulatory after the use of recombinant FSH when compared with urinary preparation, but this did not lead to a higher pregnancy rate. There was no indication for statistical heterogeneity between the trials for any of these outcomes.

Unintended effects
Since the implementation of the low-dose step-up regimen and the introduction of OHSS management protocols, the major complication of ovarian stimulation is multiple pregnancies. Due to adherence to the cancellation criteria the incidence OHSS is generally low. In the trials OHSS rates

<table>
<thead>
<tr>
<th>Table 1 Characteristics of the six included trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>References</td>
</tr>
<tr>
<td>Balen28</td>
</tr>
<tr>
<td>Revelli21</td>
</tr>
<tr>
<td>Platteau30</td>
</tr>
<tr>
<td>Yarali26</td>
</tr>
<tr>
<td>Coelingh Bennink27</td>
</tr>
<tr>
<td>Loumaye25</td>
</tr>
</tbody>
</table>

Abbreviations: CC, clomiphene-citrate; HP FSH, highly purified follicle-stimulating hormone; HP HMG, highly purified human menopausal gonadotropin.
ranged from zero to 3.2% per treatment cycle. Most were mild or moderate OHSS, with only one severe OHSS in the whole group of 856 women.

All six randomized trials reported on multiple pregnancies.25,28,30,31 Multiple pregnancies occurred in 14 of the 443 women in the recombinant FSH group and in 21 of 419 women in the urinary gonadotropin group (odds ratio 0.68; 95% CI 0.34–1.36). Most studies reported pregnancy rates after three treatment cycles. Only three trials reported the multiple pregnancy rate after the first treatment cycle.28,30,31 Pooling these data also did not reveal significant differences (OR 2.54; 95% CI 0.58–11.13) (Figure 1).

Local side effects were reported by 5 trials. Bruising, erythema, pain and itching are some of the most commonly reported reactions around the injection site. There were no indications for differences between recombinant or urinary gonadotrophin preparations. However, there were large differences in incidence of the different local reactions between trials.56 These large differences between trials were also seen for systemic side effect incidences. The most common systemic side effects were pelvic pain, nausea or headache and the incidences ranged between trials from 0% to 40%.25,28,30,31

Numerous studies have investigated the impact of fertility treatments on cancer risk in the general population. There is no evidence for an increase in cancer risk with exposure to fertility medication.34,35 Furthermore, the use of gonadotropins to induce ovulation does not appear to affect future fecundity.

**Economic evaluation of ovulation induction with follitropin alpha**

Besides effectiveness and safety, costs play an important role in deciding which treatment to give to a patient. The relative cost per gonadotropin preparation increases with its purity, but the absolute costs differ between countries.

The cost and effects of follitropin alpha and beta were compared with HP uFSH in 2 randomized controlled trials.29–31 The trial comparing follitropin alpha with HP uFSH revealed a significantly lower requirement of FSH when using follitropin alpha (Gonal-F), with mean doses of 844 IU and 668 IU per cycle respectively.29 The total costs however were higher for follitropin alpha though this difference was not statistically significant (mean cost per cycle of €208 for Gonal F versus €175 for HP uFSH).

The other trial, comparing follitropin beta and HP uFSH, also found a significantly lower requirement of FSH when using follitropin beta (Puregon) though there was no indication for a difference in duration of stimulation (mean 10.2 days versus 9.8 days).31 The total costs per cycle however were significantly higher for a follitropin beta cycle due to the lower costs per IU of HP uFSH. (mean cost per cycles for follitropin beta was €312 versus €218 for HP FSH).

Five trials compared duration of treatment and all six trials compared total the gonadotrophin dose used. We observed a significantly shorter duration of treatment with rFSH compared with uFSH (weighted mean difference [WMD] minus 1.76; 95% CI −2.59 to −0.93).26–28,30,31 Also weighted means for the total FSH dose were lower during treatment with rFSH (WMD −242; 95% CI −338 to −146).

**Patient acceptability**

It is important for patients to choose the product that meets their needs.36 Gonadotropins are injected daily for several days in follicular phase and various injection or reconstitution devices are available to facilitate self-injection.

Historically, human derived gonadotropin preparations were administered by intramuscular injections (im).
The introduction of highly purified forms of uFSH and rFSH enabled subcutaneous injection which is less painful than im administration.

In several studies the follitropin alpha and follitropin beta injection pen was compared to a conventional device. A pen was easier to use, more convenient and less painful compared to conventional syringe and vials.36–38

Patient and nurse satisfaction of follitropin alpha compared to beta were assessed in 2 randomized controlled trials. In a pilot study among 31 patients, most women favored the follitropin alpha pen over the earlier-used follitropin beta pen because preparation was faster; they were more confident of accurate dosing and had to make fewer dose adjustments. Comparable results were found in another trial among 140 women and nurses.39

Discussion
In this review we evaluated the efficacy, side effects, costs and patient acceptability of follitropin alpha and beta in ovulation induction in mainly WHO class II anovulatory women. On basis of the current best available evidence we found no differences in pregnancy and safety outcomes between the recombinant forms of FSH and urinary gonadotropins.

Both recombinant and urinary preparations are acceptable for patients. There are no indications that patients prefer one preparation over the other. The patient acceptability appears to be mainly influenced by the mode of administration.

The advantage of recombinant FSH over the urinary-derived FSH products is that small doses can easily be applied without having to use half ampoules. Furthermore there are no problems with its availability, while large quantities of urine from menopausal women are required for urofollitropin production.

The bioactivity and glycoform profile is of interest when comparing cost effectiveness. The more basic rFSH would have a higher biopotency, but this is beneficial only when it translates into lower doses of gonadotropins used and a shorter duration of stimulation leading to lower costs. Indeed, we showed in this review that the use of recombinant gonadotropins leads to a lower dosage requirement and a slightly shorter stimulation period. On the other hand, rFSH is more expensive than urinary-derived FSH products. The costs per cycle of r FSH and HP FSH were compared in 2 trials and in both the cost per cycle were higher for rFSH even though in both trials a lower FSH dose could be used.31

When comparing the effectiveness of rFSH and uFSH the differences between women with clomiphene resistance and clomiphene failure are of interest. These women probably have different fertility prospects. An individual patient data meta-analysis would be needed to differentiate between women with clomiphene resistance and clomiphene failure.

In conclusion there were no indications of a difference in effectiveness, safety and tolerability between recombinant and urinary follitropins. Follitropin alpha and beta may be more convenient to use due to the ease of self-administration, but they are also more expensive than the urinary products. Any choice the clinician makes on what gonadotropin to use for ovulation induction is a good one.

Disclosures
The authors received no funding for writing this manuscript, and declare no conflicts of interest.

References